Enterovirus A71 Vaccines

Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.

• Publication year

  2021

• Venue

  Vaccines

• Publication date

  2021-02-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/vaccines9030199PMID 33673595PMCID 7997495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

  2020cited by this paper
• Enterovirus and Encephalitis

  2020cited by this paper
• Recent Progress on the Versatility of Virus-Like Particles

  2020cited by this paper
• Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

  2020cited by this paper
• Recombinant Enterovirus 71 Viral Protein 1 Fused to a Truncated Newcastle Disease Virus NP (NPt) Carrier Protein

  2020cited by this paper
• WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines

  2020cited by this paper
• Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.

  2019cited by this paper
• Enterovirus A71: virulence, antigenicity, and genetic evolution over the years

  2019cited by this paper
• The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region

  2019cited by this paper
• Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice

  2019cited by this paper
• Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate

  2019cited by this paper
• Enterovirus A71 neurologic complications and long-term sequelae

  2019cited by this paper
• Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China

  2019cited by this paper
• Antivirals and vaccines for Enterovirus A71

  2019cited by this paper
• A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity

  2018cited by this paper
• mRNA vaccines — a new era in vaccinology

  2018cited by this paper
• Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71

  2018cited by this paper
• Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation

  2018cited by this paper
• Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development

  2018cited by this paper
• Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence

  2018cited by this paper
• VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection

  2018cited by this paper
• An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice

  2017cited by this paper
• Characterization of human enterovirus71 virus-like particles used for vaccine antigens

  2017cited by this paper
• Enteroviruses: Classification, diseases they cause, and approaches to development of antiviral drugs

  2017cited by this paper
• Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.

  2017cited by this paper
• 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study

  2017cited by this paper
• Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges.

  2016cited by this paper
• Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine

  2016cited by this paper
• Enterovirus 71 infection and neurological complications

  2016cited by this paper
• EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)

  2016cited by this paper
• Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients

  2016cited by this paper
• Review of enterovirus 71 vaccines.

  2015cited by this paper
• Update on hand-foot-and-mouth disease.

  2015cited by this paper
• High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice.

  2015cited by this paper
• Characterization of the enterovirus 71 VP1 protein as a vaccine candidate

  2015cited by this paper
• Recombinant Adeno-Vaccine Expressing Enterovirus 71-Like Particles against Hand, Foot, and Mouth Disease

  2015cited by this paper
• A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.

  2015cited by this paper
• Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity

  2015cited by this paper
• Protection against Lethal Enterovirus 71 Challenge in Mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop

  2014cited by this paper
• An inactivated enterovirus 71 vaccine in healthy children.

  2014cited by this paper
• Attenuation of Human Enterovirus 71 High-Replication-Fidelity Variants in AG129 Mice

  2014cited by this paper
• Update on the development of enterovirus 71 vaccines

  2014cited by this paper
• Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine

  2014cited by this paper
• Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.

  2014cited by this paper
• A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine.

  2013cited by this paper
• Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.

  2013cited by this paper
• Enterovirus 71 Binding to PSGL-1 on Leukocytes: VP1-145 Acts as a Molecular Switch to Control Receptor Interaction

  2013cited by this paper
• Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers

  2013cited by this paper
• Ribavirin-Resistant Mutants of Human Enterovirus 71 Express a High Replication Fidelity Phenotype during Growth in Cell Culture

  2012cited by this paper
• Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates

  2012cited by this paper
• A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71

  2012cited by this paper
• Production of EV71 vaccine candidates

  2012cited by this paper
• Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.

  2012cited by this paper
• Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.

  2012cited by this paper
• Display of VP1 on the Surface of Baculovirus and Its Immunogenicity against Heterologous Human Enterovirus 71 Strains in Mice

  2011cited by this paper
• A Single Nucleotide in Stem Loop II of 5′-Untranslated Region Contributes to Virulence of Enterovirus 71 in Mice

  2011cited by this paper
• Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo

  2011cited by this paper
• Host Factors in Enterovirus 71 Replication

  2011cited by this paper
• Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection.

  2011cited by this paper
• Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines.

  2011cited by this paper
• Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys.

  2011cited by this paper
• Clinical features, diagnosis, and management of enterovirus 71.

  2010cited by this paper
• Combined peptides of human enterovirus 71 protect against virus infection in mice.

  2010cited by this paper
• An Attenuated Strain of Enterovirus 71 Belonging to Genotype A Showed a Broad Spectrum of Antigenicity with Attenuated Neurovirulence in Cynomolgus Monkeys

  2007cited by this paper
• Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides.

  2007cited by this paper
• Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide.

  2007cited by this paper
• Expression, purification and characterization of enterovirus-71 virus-like particles.

  2006cited by this paper
• Polio eradication, cessation of vaccination and re-emergence of disease

  2004cited by this paper
• Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells

  2003cited by this paper
• Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization

  2002cited by this paper
• Glycosylation and the immune system.

  2001cited by this paper
• Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus.

  2001cited by this paper
• Induction of Hepatitis C Virus E1 Envelope Protein-Specific Immune Response Can Be Enhanced by Mutation of N-Glycosylation Sites

  2001cited by this paper
• Enterovirus 71 infections and neurologic disease--United States, 1977-1991.

  1994cited by this paper

• A randomised trial of a bioreactor-produced EV-A71 vaccine for endemic control in children.

  2026cites this paper
• Monensin and salinomycin exhibit broad-spectrum antiviral activity against enteroviruses by disrupting lysosomal acidification

  2026cites this paper
• Efficacy, Immunogenicity, and Safety of Enterovirus 71 Vaccines in Children: A Systematic Review and Meta-Analysis

  2026cites this paper
• Viral metagenomic analysis of fecal samples from Bos grunniens on the Qinghai-Tibet Plateau reveals novel picornaviruses and diverse CRESS-DNA viruses

  2026cites this paper
• Advancing peptide-based vaccines against viral pathogens: a narrative review

  2026cites this paper
• The efficacy and effectiveness of enterovirus A71 vaccines against hand, foot, and mouth disease: A systematic review and meta-analysis

  2025cites this paper
• From Dyrk1A inhibitors to a novel class of antiviral agents: Targeting Enterovirus EV-A71 with 2-aryl-substituted thiophene scaffolds.

  2025cites this paper
• Screening of Insertion Sites and Tags on EV-A71 VP1 Protein for Recombinant Virus Construction

  2025cites this paper
• Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy

  2025cites this paper
• Genetic Characterization of Enteroviruses Associated with Hand, Foot, and Mouth Disease in Yunnan Province, China, 2023.

  2025cites this paper
• Historical evolution, research hotspots and emerging trends of pediatric hand, foot, and mouth disease: a bibliometric worldview since the 21st century

  2025cites this paper
• Genotype-dependent cell tropism of EV-A71 at the human blood cerebrospinal fluid and blood brain barrier.

  2025cites this paper
• mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection

  2025cites this paper
• Clinical characteristics of fatal cases of hand, foot and mouth disease in children

  2025cites this paper
• Epidemiology of hand, foot, and mouth disease outbreaks before and during availability of EV-A71 vaccine in China's mainland: analysis of outbreak surveillance data from 2011 to 2023

  2025cites this paper
• Hand Foot and Mouth Disease Virus in Bangladesh: Serotypes, Transmission Dynamics, and Control Measures

  2025cites this paper
• CVA16 Infection Causes Neurological Injury by Engaging TLR2/MYD88/TNF-α/CXCL1 Signalling Pathway in hSCARB2 Knock-in Mice.

  2025cites this paper
• Leucoverdazyls as Novel Potent Inhibitors of Enterovirus Replication

  2024cites this paper
• Perceptions of Risk, Benefit and Trust - A Comparative Assessment Between Healthcare Workers and the General Public Towards 3 Medical Technologies

  2024cites this paper
• A multiplex one-step fluorescence quantitative differential diagnosis method for severe hand, foot and mouth disease caused by coxsackievirus A16.

  2024cites this paper
• Enterovirus-A71 exploits RAB11 to recruit chaperones for virus morphogenesis

  2024cites this paper
• Identification of the proteolytic signature in CVB3-infected cells

  2024cites this paper
• Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study

  2024cites this paper
• Benzocaine-N-acylindoline conjugates: synthesis and antiviral activity against Coxsackievirus B3

  2024cites this paper
• Beyond Poliomyelitis: A 21-Year Study of Non-Polio Enterovirus Genotyping and Its Relevance in Acute Flaccid Paralysis in São Paulo, Brazil

  2024cites this paper
• Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.

  2024cites this paper
• Efficient Production of Enterovirus 71 (EV71) Virus-like Particles by Controlling Promoter Strength in Insect Cells

  2024influential citation
• Recent Progress in Innate Immune Responses to Enterovirus A71 and Viral Evasion Strategies

  2024cites this paper
• The Repurposing of Cellular Proteins during Enterovirus A71 Infection

  2023cites this paper
• Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate

  2023cites this paper
• Insertion of an Amphipathic Linker in a Tetrapodal Tryptophan Derivative Leads to a Novel and Highly Potent Entry Inhibitor of Enterovirus A71 Clinical Isolates

  2023cites this paper
• Hand, Foot, and Mouth Disease Challenges and Its Antiviral Therapeutics

  2023cites this paper
• Antiviral properties of verdazyls and leucoverdazyls and their activity against group B enteroviruses

  2023cites this paper
• EV-A71 Mechanism of Entry: Receptors/Co-Receptors, Related Pathways and Inhibitors

  2023cites this paper
• Addressing vaccine-preventable encephalitis in vulnerable populations

  2023cites this paper
• Effect of proteins isolated from Brazilian snakes on enterovirus A71 replication cycle: An approach against hand, foot and mouth disease

  2023cites this paper
• An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents.

  2023cites this paper
• Recent Updates on Peptide Molecules in Drug and Vaccine Development.

  2023cites this paper
• Enterovirus A71-associated acute flaccid paralysis in a pediatric patient: a case report

  2023cites this paper
• Enterovirus-A71 exploits Rab11 to recruit chaperones for virus morphogenesis

  2023cites this paper
• Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.

  2023cites this paper
• Molecular evolutionary dynamics of enterovirus A71, coxsackievirus A16 and coxsackievirus A6 causing hand, foot and mouth disease in Thailand, 2000–2022

  2023cites this paper
• Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study

  2023cites this paper
• Preventing enterovirus A71 disease: another promising vaccine for children.

  2022cites this paper
• Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.

  2022cites this paper
• Nuôi cấy virus EV71 trong hệ thống lắc cho sản xuất vắc xin phòng bệnh tay, chân, miệng

  2022cites this paper
• In Silico and In Vitro Antiviral Activity Evaluation of Prodigiosin from Serratia marcescens Against Enterovirus 71

  2022cites this paper
• Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3

  2022cites this paper
• Respiratory illness virus infections with special emphasis on COVID-19

  2022cites this paper
• Coxsackievirus A6 was the most common enterovirus serotype causing hand, foot, and mouth disease in Shiyan City, central China

  2022cites this paper
• The Bottlenecks of Preparing Virus Particles by Size Exclusion for Antibody Generation

  2022cites this paper
• Enterovirus vesicular stomatitis with exanthema: Epidemiological Features and Vaccination

  2022cites this paper
• Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial

  2022cites this paper
• Molecular Epidemiology of Enterovirus A71 in Surveillance of Acute Flaccid Paralysis Cases in Senegal, 2013–2020

  2022cites this paper
• Insight into the Enterovirus A71: A review

  2022cites this paper
• Update on Viral Infections Involving the Central Nervous System in Pediatric Patients

  2021cites this paper
• First evidence of enterovirus A71 and echovirus 30 in Uruguay and genetic relationship with strains circulating in the South American region

  2021cites this paper
• Enterovirus Diseases and Vaccines

  2021cites this paper
• Upaya Pencegahan Hand, Foot, and Mouth Disease Berat Melalui Vaksinasi Enterovirus 71

  year unknowncites this paper